APP下载

贝伐珠单抗联合TP方案化疗对晚期子宫颈癌 患者血清肿瘤标志物及不良反应的影响

2025-08-10鄢平平熊星辉

中国医学创新 2025年19期
关键词:贝伐珠子宫颈癌单抗

The Influence of Bevacizumab Combined with TP Regimen Chemotherapy on Serum Tumor Markers and Adverse Reactions inPatients with Advanced Cervical Cancer/, .// Medical Innovation of China,2025,22(19): 010-014

[Abstract]Objective: To explore the effcts of Bevacizumab and TP regimen (Paclitaxel plus Cisplatin) chemotherapy onserum tumor markers and adverse reactions in patients with advancedcervical cancer.Method: A total of 86 patients with advanced cervical cancer admited to Fengcheng People's Hospital from June2O21 to December 2023 were selected as the subjects.They were divided into two groups according to the random number table method, with 43 cases in each group.The control group was treated with the TP regimen, while the observation group was treated with Bevacizumabinaddition to thecontrol group.Theclinical eficacy,serum tumor markers,Tcellsubsets, tumor diameter,qualityof life and adverse reactions of thetwo groups were compared.Result: After treatment,the total effective rate of the observation group was higher than that of the control group ( P lt;0.05).After treatment, the levels of carbohydrate antigen 19-9 (CA19-9),carcinoembryonic antigen (CEA),squamous cell carcinoma antigen (SCC-Ag),cytokeratin 19 fragment (Cyfra 21-1),and carbohydrate antigen 125 (CA125) in the observation group were lower than those in the control group ( P lt;0.05).Aftertreatment, thelevelsof Th1and Th2and Th1/Th2 in the observation group were all lower than those in the control group ( P lt;0.05).After treatment,the tumor diameter in the observationgroup wassmaler than that in thecontrol group,and theoverallimprovementof the qualityof life in the observation group was better than that in the control group ( P lt;0.05). Regarding adverse reactions, there was no statistically significant difference between the two groups ( Pgt;0.05 ).Conclusion:The combination of Bevacizumab andthe TP regimen can efectively improvethe levels of serum tumor markersand Tcellsubsets in patients with advanced cervical cancer,reduce the tumor diameter,improve the qualityof life,and does not increase obvious adverse reactions,with relatively high safety.

子宫颈癌是一种妇科恶性肿瘤,在临床较为常见,原发于子宫颈,发病率及病死率高[-2]。该病初期症状不显著,很多患者被确诊时多已处于疾病的晚期阶段,临床治疗难度较大。以往临床主要采用TP化疗方案治疗此病,但并不能完全控制病灶转移及肿瘤生长,治疗效果存在一定局限性[3。贝伐珠单抗作为一种分子靶向药,是现阶段治疗晚期子宫颈癌的有效方法,可抑制血管生长及肿瘤细胞增殖[4。研究表明,靶向治疗和放化疗联合治疗晚期子宫颈癌效果更佳[5]。基于此,本研究通过随机分组对照,分析贝伐珠单抗与TP方案联合治疗对子宫颈癌患者的影响,报道如下。

1资料与方法

1.1一般资料

将丰城市人民医院2021年6月—2023年12月收治的86例晚期子宫颈癌患者按照随机数字表法分为两组,各43例。(1)纳入标准: ① 参考《2018年FIGO分期》,利用影像学及病理学检查诊断符合晚期子宫颈癌指征; ② 无精神疾病史; ③ 病例资料齐全; ④ 无药物过敏史; ⑤ 无化疗禁忌证; ⑥ 临床分期为IV期; ⑦ 预计生存时间 ⩾3 个月。(2)排除标准: ① 入组前一个月内曾接受过其他治疗; ② 因个人原因中途退出研究; ③ 合并其他恶性肿瘤; ④ 严重精神障碍,已丧失正常沟通能力; ⑤ 患有子宫颈炎、子宫颈糜烂等感染性病症。本研究经丰城市人民医院医学伦理委员会审批通过。患者及家属对本研究知情,并签署书面同意书。

1.2方法

对照用TP方案治疗:紫杉醇注射液(海南金星制药有限公司,国药准字H20084032, 5mL :30mg ) + 顺铂(齐鲁制药有限公司,国药准字H37021358, 10mg )。紫杉醇注射液:静脉滴注,剂量为 175mg/m2 ,滴注时间大于 3h ,1次/d;……

登录APP查看全文

猜你喜欢

贝伐珠子宫颈癌单抗
卡瑞利珠单抗联合化疗用于我国宫颈癌患者的药物经济学评价
伏美替尼联合贝伐珠单抗治疗表皮生长因子受体基因突变肺腺癌伴脑转移的效果分析
基于CBCT和六维床比较分析两种固定方式在子宫颈癌术后放疗中的摆位误差
抗体药物治疗复发/难治性弥漫性大B细胞淋巴瘤的研究进展
非霍奇金淋巴瘤患者MS4A1基因多态性与利妥昔单抗血药浓度及疗效的相关性研究
免疫治疗:肺癌的“革命性疗法”